Related Experiment Videos
Characterization of vigabatrin-associated optic atrophy
Lars Frisén1, Kristina Malmgren
1Institute of Clinical Neuroscience, Sahlgren's Academy at Gothenburg University, SE-413 45 Gothenburg, Sweden. lars.frisen@neuro.gu.se
Acta Ophthalmologica Scandinavica
|September 27, 2003
Summary
This study identified a new type of optic atrophy linked to the anti-epileptic drug vigabatrin. Ocular fundus imaging can help monitor patients for this irreversible visual toxicity.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Vigabatrin is an anti-epileptic drug with known potential toxicities.
- Optic atrophy is a condition characterized by damage to the optic nerve.
Purpose of the Study:
- To report the discovery of a novel form of optic atrophy associated with vigabatrin use.
- To characterize the pattern and severity of this vigabatrin-induced optic atrophy.
Main Methods:
- Retrospective analysis of 25 patients treated with vigabatrin.
- Utilized digitally enhanced ocular fundus photographs and kinetic visual field maps.
- Correlated fundus findings with visual field defects and cumulative drug dosage.
Main Results:
- 84% of patients showed subtle, diffuse retinal nerve fibre layer atrophy.
- Atrophy scores correlated with visual field preservation and vigabatrin dose.
- A proposed pathophysiological model involves intraocular retinal ganglion cell axon lengths.
Conclusions:
- Optic atrophy indicates irreversible visual toxicity from vigabatrin.
- Ocular fundus imaging is a valuable tool for monitoring vigabatrin-treated patients for visual toxicity.